Catalent Inc (NYSE:CTLT) Director Donald E. Morel, Jr. bought 10,000 shares of the stock in a transaction that occurred on Thursday, September 13th. The stock was purchased at an average price of $43.00 per share, for a total transaction of $430,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Catalent stock traded down $0.40 during mid-day trading on Monday, reaching $42.60. The company had a trading volume of 28,275 shares, compared to its average volume of 829,105. The company has a debt-to-equity ratio of 2.44, a current ratio of 2.15 and a quick ratio of 1.79. Catalent Inc has a 52 week low of $36.73 and a 52 week high of $47.87. The company has a market cap of $6.07 billion, a PE ratio of 27.06, a price-to-earnings-growth ratio of 2.49 and a beta of 1.42.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.06. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The firm had revenue of $685.30 million during the quarter, compared to the consensus estimate of $690.69 million. During the same period in the prior year, the firm earned $0.65 EPS. The business’s revenue was up 11.1% on a year-over-year basis. analysts expect that Catalent Inc will post 1.72 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the business. Summit Trail Advisors LLC boosted its holdings in Catalent by 2,021.9% in the 1st quarter. Summit Trail Advisors LLC now owns 103,210 shares of the company’s stock valued at $103,000 after purchasing an additional 98,346 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new stake in Catalent in the 2nd quarter valued at $145,000. Moneta Group Investment Advisors LLC boosted its holdings in Catalent by 105.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after purchasing an additional 1,800 shares during the period. Point72 Asia Hong Kong Ltd boosted its holdings in Catalent by 35,700.0% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 3,938 shares of the company’s stock valued at $162,000 after purchasing an additional 3,927 shares during the period. Finally, Hartford Investment Management Co. bought a new stake in Catalent in the 2nd quarter valued at $220,000. 92.17% of the stock is owned by hedge funds and other institutional investors.
A number of research firms recently issued reports on CTLT. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 target price on the stock in a research note on Monday, July 9th. JPMorgan Chase & Co. raised their target price on shares of Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Wednesday, August 29th. Finally, ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $48.70.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: What is intrinsic value?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.